2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.10 Grant

PP01.10 Grant - Abstract

Pdf Summary

The document discusses the efficacy of afatinib in patients with tumors containing the uncommon EGFR exon 19 deletion, L747_A750delinsP. This mutation is less sensitive to certain EGFR tyrosine kinase inhibitors compared to the common del19 E746_A750del. However, preclinical studies suggest that afatinib, a second-generation TKI, may be more effective for targeting tumors with the L747_A750delinsP mutation. The pooled analysis included data from four clinical trials and compared outcomes of patients with E746_A750del and L747_A750delinsP mutations when treated with afatinib. The study found that patients with L747_A750delinsP mutation had a higher objective response rate (87.5%) compared to E746_A750del (76%) but similar median progression-free survival and overall survival. The results suggest that afatinib could be a preferred treatment for patients with EGFR NSCLC harboring the L747_A750delinsP mutation. Further prospective studies are needed to compare afatinib with other TKIs for this patient population.

Keywords

afatinib

EGFR exon 19 deletion

L747_A750delinsP mutation

EGFR tyrosine kinase inhibitors

second-generation TKI

pooled analysis

clinical trials

objective response rate

progression-free survival

overall survival